论文部分内容阅读
１２２例轻，中度原发性高血压患者分为两组，予口服阿罗洛尔（ａｒｏｔｉｎｏｌｏｌ，ａｌｍａｒｌ）或对照药阿替洛尔（ａｔｅｎｏｌｏｌ）。以随机、双盲对照法，对其疗效及不良反应进行了研究。阿罗洛尔组依次递增剂量１０－１５ｍｇｂｉｄ，４周后平均坐位血压由治疗前２１．８／１３．４ｋＰａ（１６３．７／１００．７ｍｍＨｇ）降至１９．７／１１．９ｋＰａ（１４８．１／８９．１ｍｍＨｇ），总有效率为７６％，１０ｍｇｂｉｄ，显效率为７２．１％。阿替洛尔组依次递增剂量为１２．５－２５ｍｇｂｉｄ，４周后平均坐位血压由治疗前的２１．８／１３．４ｋＰａ（１６３．５／１００．４ｍｍＨｇ）降至１９．５／１１．７ｋＰａ（１４６．１／８７．９ｍｍＨｇ）总有效率为８０％，１２．５ｍｇｂｉｄ，显效率为６９．２％。两组间临床疗效无显著性差异。两组日服二次法，均可较平稳地控制２４ｈ血压，保持时辰节律。两组中常见不良反应为头晕、失眠及乏力，在继续服药中，逐渐减轻，部分症状消失，两组均无因不良反应而退出试验者。两组实验室检查无明显异常。２０例服阿罗洛尔治疗半年的患者，疗效保持稳定，实验室检查及体重亦未发现明显异常。结果表明，阿罗洛尔的临床疗效和药物不良反应?
122 patients with mild to moderate essential hypertension were divided into two groups: oral administration of arotinolol (almarl) or control drug, atenolol. A randomized, double-blind control method, its efficacy and adverse reactions were studied. Arotinolol group followed by increasing doses of 10-15mgbid, 4 weeks after the average blood pressure decreased from 21.8 / 13.4kPa (163.7 / 100.7mmHg) before treatment to 19.7 / 11.9kPa (148.1 / 89.1mmHg), the total effective rate was 76%, 10mgbid, significant efficiency was 72.1%. Atenolol group followed by an increasing dose of 12.5-25mgbid, after 4 weeks mean sitting blood pressure decreased from 21.8 / 13.4kPa (163.5 / 100.4mmHg) before treatment to 19.5 / 11.7kPa (146.1 / 87.9mmHg) total effective rate of 80%, 12.5mgbid, markedly efficient 69.2%. There was no significant difference in clinical efficacy between the two groups. Two groups on the second service, can be more stable control of 24h blood pressure, keep the hour rhythm. Two groups of common adverse reactions were dizziness, insomnia and fatigue, continue to take medication, gradually reduced, some of the symptoms disappear, no adverse reactions in both groups withdrew from the test. Two sets of laboratory tests no obvious abnormalities. Twenty patients treated with arotinolol for six months remained stable with no significant abnormalities in laboratory tests and body weight. The results show that the clinical efficacy of arotinol and adverse drug reactions?